1. Strong Industry Partnerships

At Least One Large Pharma Company in the Cap Table We partner with some of the major pharmaceutical companies and top venture capitalists, enhancing our access to high-quality investments and demonstrating our strong industry connections.

Insight: In the last 500 company failures, only 20 had one pharma company in their cap table, and only 4 had more than one large pharma involved. This underscores the importance of having substantial pharma backing to mitigate risks and bolster success.

2. Established Venture Capital Support

At Least One Established VC with a Successful Track Record We invest in companies that are backed by at least one established venture capital firm with a proven track record. This ensures that the company has robust financial support and strategic guidance, which are crucial for navigating the complexities of the biotech industry.

Insight: Among the last 500 failed companies, only 14 had more than one well-known biotech VC in their cap table. This highlights the importance of having reputable VC support to drive company growth and stability.

3. Focus on Later Stages of Development

No Drug Discovery Stage or Early Preclinical Companies We avoid investing in companies at the drug discovery stage or early preclinical phase due to the high risks and extended timelines associated with these stages. Instead, we focus on companies that have progressed to the IND phase through Phase 2, where they have demonstrated proof of concept and have a clearer path to market.

4. Investment Focus on Four Key Therapeutic Areas

Dreavent Capital targets investments in biotech companies backed by large pharma companies and well-known biotech funds within four key therapeutic areas: Immunology & Inflammation, Oncology, Cardiovascular & Metabolic and Neuroscience, with an emphasis on Immunology and Inflammation due to its broad impact on disease treatment and innovation potential.